At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Genetic Testing in Guiding Treatment for Patients with Brain Metastases
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, GDC-0084, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.
In order to participate you must meet the following criteria:
- Have histologically confirmed metastatic disease to the brain from any solid tumor.
- Have measurable CNS disease (> 10mm).
- Have presence of clinically actionable alteration in NTRK, ROS1, or CDK pathway or PI3K pathway in both a brain metastasis and extracranial site.
- Have tissue available for biomarker testing (any brain metastasis tissue and extracranial site from any prior resection or biopsy).
This is a partial list of elgibility requirements. To inquire about your eligibility, please call the contact number provided.